GSK’s Zejula reduces risk of progression and death in mesothelioma study
Data from the NERO study was presented at the American Association of Cancer Research (AACR) Annual Meeting 2025.
Therapy Area
Boehringer, Oxford University and Cumulus to explore brain activity in BPD
AstraZeneca’s Truqap fails in another Phase III trial
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM
Biohaven secures $600m financing as it awaits FDA prodrug decision
EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma
France halts Valneva’s chikungunya vaccine use in seniors
